Introduction
============

Nontuberculous mycobacteria (NTM) are ubiquitous organisms that can be isolated from the environment, including water and soil[@B1], and they cause pulmonary and extrapulmonary disease[@B2][@B3]. Pulmonary disease (PD) is the most common clinical presentation of NTM infection, and although the cause of NTM-PD development is not clearly understood, it may be associated with both host and bacterial factors[@B4][@B5][@B6][@B7]. *Mycobacterium avium* complex (MAC) is the most common cause of NTM-PD worldwide[@B4][@B5][@B6][@B7].

The number of recognized NTM organisms is increasing, with more than 180 species currently recognized (<http://www.bacterio.net/mycobacterium.html>). The distribution of NTM species varies widely according to geography8. The number of MAC organisms is also increasing and currently includes *M. avium*, *M. intracellulare*, *M. chimaera*, *M. arosiense*, *M. bouchedurhonense*, *M. colombiense*, *M. marseillense*, *M. timonense*, *M. vulneris*, and *M. yongonense*[@B4]. Within the complex, *M. avium*, *M. intracellulare*, and *M. chimaera* are the most common human pathogens[@B4]. The distribution of each MAC organism varies according to country; for example, *M. chimaera* is relatively rare in South Korea[@B9][@B10] but common in Germany[@B11]. Notably, *M. chimaera* is less virulent than *M. avium* or *M. intracellulare*[@B11][@B12], and the recurrence rates of MAC-PD after successful treatment completion also may differ for MAC species[@B12].

MAC-PD has two different clinical phenotypes: the fibrocavitary and nodular bronchiectatic forms[@B4][@B5][@B6][@B7]. The fibrocavitary form is typified by a cavitary lesion in the upper lobes and is usually associated with other pulmonary diseases. For example, the lesions can stem from scars from previous pulmonary tuberculosis and/or chronic obstructive pulmonary disease, which frequently develops in older men and shows rapid progression[@B2]. The nodular bronchiectatic form is characterized by bilateral bronchiectasis with multiple nodules and tree-inbud opacities often in the right middle lobe and the lingular segment of the left upper lobe on high-resolution computed tomography (HRCT)[@B2]. This form usually occurs in postmenopausal, non-smoking females and has a slow progression[@B2]. Additionally, cavitary lesions can also be associated with the nodular bronchiectatic forms[@B13][@B14][@B15][@B16][@B17].

The incidence and prevalence of NTM-PD are increasing worldwide, affecting both immunocompetent and immunocompromised individuals[@B18][@B19]. In South Korea, the frequency of NTM isolation from clinical specimens and the number of patients with NTM-PD have been increasing over the past decade[@B7], which may be mainly due to the increasing incidence of MAC-PD[@B20]. Although *M. intracellulare* was more prevalent than *M. avium* among MAC-PD cases in the past, *M. avium* has recently become more frequently isolated than *M. intracellulare* in South Korea[@B20][@B21][@B22][@B23][@B24]. Despite the increasing prevalence of MAC-PD, its treatment remains difficult. In this report, we review the treatment of MAC-PD.

Natural Course of Disease and Decision on Treatment Initiation
==============================================================

Diagnosis of MAC-PD does not require immediate initiation of treatment[@B2][@B3], and understanding the potential for progression is very important. A significant proportion of patients with MAC-PD (approximately 40%--60%) remain without disease progression for several years after diagnosis, even without treatment[@B12][@B13][@B15][@B25][@B26]. Moreover, approximately 40%--50% of patients with untreated MAC-PD achieve spontaneous negative culture conversion without antibiotic treatment[@B26][@B27][@B28]. Therefore, to avoid unnecessary treatments that might cause unwarranted medical expenses and adverse drug reactions, clinicians should consider the risk of disease progression and make timely decisions in the treatment initiation phase ([Figure 1](#F1){ref-type="fig"}).

Important prognostic factors related to the progression of MAC-PD are low body mass index and poor nutritional status[@B13][@B26][@B27][@B29][@B30], the presence of cavitary lesions[@B13][@B15][@B25][@B26][@B30], extensive disease[@B26][@B29], and positive acid-fast bacilli (AFB) smears[@B25][@B26][@B27], although this evidence has been supported by case series rather than by randomized, controlled studies.

Antibiotic Treatment
====================

Patients with MAC-PD have different treatment prognoses based on the severity of an individual patient\'s disease, previous treatment history, and resistance of the strain to various drugs[@B2][@B3]. The American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines published in 2007 recommend that a macrolide-based, three-drug combination regimen, consisting of macrolides (clarithromycin or azithromycin) with rifampin and ethambutol, should be administered for at least 12 months after sputum cultures convert to negative[@B2]. This regimen can be strengthened by adding parenteral drugs, such as streptomycin or amikacin, for patients with severe and extensive, especially fibrocavitary disease. The frequency of administration of the treatment regimen is also different: three times per week administration is recommended for patients with non-cavitary nodular bronchiectatic disease; and a daily treatment is recommended for cavitary MAC-PD ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). Intermittent therapy has potential benefits for decreasing adverse drug effects and medication costs and for increasing adherence to medication[@B31][@B32]. The recent British Thoracic Society (BTS) guidelines, published in 2017, basically recommend the same treatment regimen, consisting of a macrolide-based, three-drug combination regimen for MAC-PD[@B3]. The BTS guidelines also recommend two different treatment regimens, i.e., intermittent therapy for non-severe MAC-PD and daily therapy for severe MAC-PD. However, the indications differ slightly from those of the previous ATS/IDSA guidelines. The BTS guidelines recommend against using an intermittent oral antibiotic regimen in patients with severe MAC-PD, such as in cases with AFB smear-positive respiratory tract samples, radiologic evidence of lung cavitation/severe infection, or severe symptoms/signs of systemic illness[@B3], and therefore do not limit daily treatment to only cavitary disease. These two sets of guidelines, which suggest the same regimens for treating MAC-PD, were primarily based on the outcomes of observational cohort studies, case series, and expert opinions due to a paucity of randomized, controlled trials for this disease[@B4]. However, adherence to the recommended regimens of the current guidelines has been found to be poor[@B33][@B34].

Treatment Outcomes
==================

Since 2004, five systematic reviews and meta-analyses have been published on treatment outcomes for MAC-PD ([Table 1](#T1){ref-type="table"})[@B35][@B36][@B37][@B38][@B39]. The treatment success rates in individual studies varied because of their significant heterogeneity, including different definitions of treatment outcomes, inclusion and exclusion criteria, disease severities, regimens, and dosages. The pooled treatment success rates in the five systematic reviews ranged from 32% to 65%, and 12%--16% of the enrolled patients had not completed treatment[@B35][@B36][@B37][@B38][@B39]. In a subgroup analysis of these systematic reviews, macrolide-containing regimens showed better outcomes compared to those without macrolides[@B35][@B36][@B37][@B38][@B39]. Furthermore, use of the triple-drug regimens recommended by the ATS/IDSA was also associated with better outcomes, and the success rates of these regimens further increased for macrolide-susceptible patients and those with previously untreated MAC-PD when the drugs were taken for at least one year[@B39].

Although the pooled success rate of treatment in the meta-analysis was relatively low, culture conversion rates were relatively high in recent large cohort studies among patients with MAC-PD who received more than 12 months of the recommended three-drug therapy (74%--88%)[@B17][@B31][@B32][@B40]. Among these large cohort studies, one recent study of 481 patients with MAC-PD in South Korea showed that treatment outcomes differed according to clinical phenotypes[@B17]. A favorable outcome, defined as sputum culture conversion after initiation of treatment and maintenance of negative culture for at least 12 months of treatment, was higher in patients with non-cavitary nodular bronchiectatic disease (88%) compared to those with cavitary nodular bronchiectatic (78%) and fibrocavitary disease (76%) (p\<0.05), regardless of the use of daily treatment and streptomycin with the latter two phenotypes[@B17]. However, it should be noted that this study did not use an intention-to-treat analysis and excluded 85 patients who did not complete at least 12 months of treatment due to drug intolerance, follow-up loss, death, and lack of perceived benefit; if these patients had been included in the denominator, the overall success rate would be reduced from 84% to 71%[@B41].

Regarding the frequency of treatment, intermittent therapy given three times weekly shows comparable high treatment success rates with high tolerability and requires fewer regimen modifications when compared to daily therapy[@B31][@B32]. Adverse effects such as visual disturbance or optic neuropathy due to ethambutol are less likely to be observed in intermittent therapy than in daily therapy[@B32][@B42]. Therefore, this intermittent treatment should be considered in patients with non-cavitary nodular bronchiectatic disease, in contrast to patients with cavitary MAC-PD in which intermittent therapy results in low culture conversion rates and low HRCT improvement[@B43]. Although the usually recommended dose of azithromycin is 250 mg[@B2][@B3], sometimes a 500 mg daily dose of azithromycin is also recommended especially for cavitary MAC-PD[@B44][@B45] ([Table 2](#T2){ref-type="table"}).

Nevertheless, overall, the treatment success rate with the combination antibiotic regimen has been unsatisfactory, and a substantial proportion of patients remain culture-positive with refractory MAC-PD despite long-term antibiotic therapy[@B36][@B37][@B38][@B39]. In patients with refractory MAC-PD who undergo long-term macrolide therapy, however, macrolide resistance develops infrequently[@B31][@B32]. A recent study showed that refractory MAC-PD was commonly caused by frequent reinfection with new MAC strains during antibiotic treatment rather than by persistence of the original strains, which could help to explain the infrequent development of macrolide resistance in patients with refractory MAC-PD[@B46].

Although microbiologic recurrences of MAC-PD, even after successful completion of antibiotic therapy, are relatively common, optimum treatment approaches for recurrent disease have not been determined. Treatment outcomes in patients with a history of previous treatment of MAC-PD tend to be worse than the outcomes in newly treated patients[@B47][@B48][@B49][@B50], and therefore a strengthened regimen that includes a daily macrolide-containing three drug regimen combined with parenteral amikacin or streptomycin is recommended for these patients with recurrent MAC-PD[@B2]. However, evidence suggests that the majority of MAC recurrences after therapy completion are reinfections rather than relapses or treatment failures[@B17][@B31], and so these strengthened regimens might be excessive and cause unnecessary adverse drug reactions. A recent cohort study showed that a three-times-weekly intermittent therapy in patients with previously treated non-cavitary nodular bronchiectatic MAC-PD achieved a high sputum culture conversion rate that was comparable with that of daily therapy (82% vs. 81%, p=0.999)[@B51]. Therefore, intermittent treatment could be considered in patients with recurrent non-cavitary nodular bronchiectatic MAC-PD when the isolate remains susceptible to macrolides.

Macrolide-Resistant MAC-PD
==========================

The treatment of patients with macrolide-resistant MAC-PD is challenging because of very poor treatment outcomes and lack of effective drugs[@B52][@B53][@B54][@B55]. For macrolide-resistant MAC-PD, culture conversion rates of only 15%--36% have been reported as well as 2-year and 5-year mortalities of 9%--15% and 47%[@B53][@B54], respectively. Risk factors for the development of macrolide resistance are macrolide monotherapy, the use of macrolide plus rifampin without ethambutol, and the use of macrolide in combination with fluoroquinolone only[@B52][@B53][@B54][@B55]. Therefore, these treatment regimens should be avoided for the treatment of MAC-PD, especially in patients with high bacterial burden such as in cavitary disease. However, macrolide-resistant MAC can still develop in some patients treated with guideline-based therapy[@B53][@B54]. In cases where sputum is persistently AFB smear-positive during treatment, even when guideline-based treatment is used, the patient should be carefully monitored for the development of macrolide resistance.

The recently published BTS guidelines recommend adding additional drugs such as isoniazid or moxifloxacin and intravenous or nebulized amikacin to the standard antibiotic treatment for macrolide-resistant disease, although the efficacy of these treatments remains inconclusive[@B3]. One study looked at 41 patients with refractory MAC-PD that was defined as a persistent AFB smear-positive sputum culture for at least six months after initiation of a macrolide-based standard regimen; the addition of moxifloxacin was associated with culture conversion in 33% of the patients with macrolide susceptible isolates but none of the patients with macrolide resistant isolates[@B56].

Surgical Treatment
==================

Because the success rate of medical therapy alone for MAC-PD has not been suboptimal, and many patients experience treatment failure or macrolide resistance that cannot be successfully treated with medical therapy alone, adjuvant lung resection surgery should be considered in select patients to improve treatment outcomes[@B2][@B3]. The culture conversion rate following surgical treatment has been as high as 80%--100%, despite the fact that most studies included patients who experienced treatment failure[@B57][@B58]. Reported postoperative mortality and morbidity have varied considerably, ranging from 0% to 23% and 0% to 50%, respectively[@B57][@B58]. Mortality and morbidity were higher in those who underwent pneumonectomy compared to those who had other operative procedures[@B57][@B58]. However, mortality and morbidity decreased from the early to the late phase of the study period in a large cohort study conducted at a single, experienced center[@B59]; this improvement was likely associated with improved patient selection, better preoperative assessments including nutritional assessment and antibiotic therapy as a part of a multidisciplinary treatment approach, surgical techniques, and postoperative measures.

Surgical resection is most commonly indicated due to treatment failures during medical therapy; however, other indications also include hemoptysis, cavitary disease, destructive lung lesions, and lung nodules that are limited in site and extent. Because treatment failure can be expected in patients with a positive culture despite 6--12 months of therapy, surgical therapy should be considered in these patients. Considering the recommended treatment duration of 12 months after sputum culture conversion to negative, postoperative antibiotic treatment should also be administered for 12 months if sputum culture conversion is achieved after surgical resection[@B60].

Studies on surgical resection for NTM-PD have been retrospective and performed in several experienced centers. Therefore, there could be a selection bias, and the treatment outcomes, such as treatment success and complication rates of surgical resection, might not be generalizable. Because of the significant postoperative morbidity and mortality involved, guidelines recommend that the performance of lung resection surgery be based on a rigorous risk-benefit analysis in a multidisciplinary setting, in an experienced center[@B2][@B3].

Novel Therapeutic Agents
========================

Although macrolide-containing regimens have improved treatment outcomes for MAC-PD, multiple drugs and a long duration of treatment can cause multiple adverse drug reactions, and therefore, the treatment success rate of this regimen is still unsatisfactory. Moreover, macrolide-resistant MAC-PD is usually refractory to current medical treatments. Even after successful treatment, a significant number of recurrences occur, contributing to the suboptimal treatment success rate for MAC-PD. Therefore, novel therapeutic agents are needed to improve treatment outcomes.

The drug clofazimine was developed for tuberculosis in the 1950s but was ultimately used to treat leprosy. Recently, this drug has been used for the treatment of multidrug-resistant tuberculosis, with good efficacy[@B61]. Its efficacy for MAC-PD was shown in two cohort studies from a single institute in Canada, in which regimens consisting of a macrolide, ethambutol, and clofazimine were utilized, and 87% (26/30) and 99% (92/93) of patients achieved culture conversion[@B62][@B63]. Adverse drug reactions related to clofazimine in these two studies included skin color changes (≥5%). In a recent large cohort study of 112 patients with MAC and/or *M. abscessus* infections, most of whom had refractory disease and some of whom also had cystic fibrosis, clofazimine was included in the regimen, and the culture conversion rate for patients with MAC-PD was 42% (11/26)[@B64]. In this study, skin-related adverse drug reactions, including skin discoloration, dryness, or sun hypersensitivity, were the most common (66%), followed by gastrointestinal (55%) and neurologic (42%) adverse drug reactions; clofazimine was discontinued in 14% of patients due to the adverse drug reactions[@B64]. Although clofazimine can have side effects, given its efficacy, its use should be considered when the guideline-recommended regimen is not administered due to adverse drug reactions, drug-drug interactions, or drug resistance.

Injectable aminoglycosides, including amikacin and streptomycin, have been recommended for MAC-PD if the disease is associated with cavitary disease or macrolide resistance[@B2][@B3]. However, serious systemic side effects, including auditory, vestibular, and renal toxicity could limit the long-term systemic administration of these drugs. Administering amikacin by inhalation may be an effective alternative for increasing the efficacy of the drug and decreasing adverse drug reactions. Although recent BTS guidelines recommended this treatment for severe or macrolide-resistant MAC-PD, reports on this approach are limited. Case series using different doses and frequencies of administration of inhaled amikacin in refractory cases with MAC or *M. abscessus* infections showed variable culture conversion rates (25%--43%) and adverse drug reaction rates (8%--35%)[@B65][@B66]. Recently, in a large cohort study from South Korea involving 77 patients with refractory NTM-PD (*M. abscessus*, n=48; MAC, n=20; mixed infection, n=9), all of whom received amikacin inhalation therapy, culture conversion was achieved in 18% of the cases overall and 15% of the MAC-PD cases[@B67]. In the same study, adverse drug reactions such as ototoxicity to the amikacin inhalation therapy developed in 38% of all patients, and this therapy was discontinued in 27% of patients[@B67]. Although these studies showed clinical and microbiologic improvements in some patients, the treatment was associated with common adverse reactions. In order for inhaled amikacin to be used more widely, optimal dosing and frequency of administration will need to be determined to reduce adverse reactions and improve efficacy.

Previous studies used an injectable formulation of amikacin; however, recently a novel amikacin formulation was developed, i.e., liposomal amikacin for inhalation[@B68]. Liposomal amikacin comprises a small, charge-neutral, highly biocompatible liposome with encapsulated amikacin, a formulation that can enhance drug delivery and may lead to improved efficacy and decreased toxicity[@B68]. A phase II, double-blind, randomized, placebo-controlled trial for this drug in patients with refractory NTM-PD, including both MAC and *M. abscessus*, was recently published[@B69]. In this study, the treatment group showed a significantly higher proportion of patients with negative cultures at 84 days compared to that of the placebo group (32% vs. 9%, p=0.006)[@B69]. However, adverse drug reactions commonly developed in the treatment group, such as dysphonia, bronchiectasis exacerbation, cough, oropharyngeal pain, fatigue, chest discomfort, wheezing, and infective pulmonary exacerbation of cystic fibrosis[@B69]. A phase III, randomized, open-label study on refractory MAC-PD, recently released as a conference abstract, showed a higher proportion of negative cultures at six months in patients treated with liposomal amikacin inhalation therapy in addition to guideline-based therapy compared to patients treated with guideline-based therapy only (29% vs. 9%, p\<0.001)[@B70]. However, respiratory adverse drug reactions were more common in patients taking the inhalation therapy when compared to the control patients (87% vs. 50%), although there were no safety issues for this drug related to nephrotoxicity or ototoxicity.

Bedaquiline is a novel diarylquinoline targeting the proton pump of adenosine triphosphate synthase in *M. tuberculosis*[@B71][@B72]. The drug was developed to treat multidrug-resistant tuberculosis and has good efficacy and safety when used in combination with the World Health Organization\'s recommended background regimen for multidrug-resistant tuberculosis. Bedaquiline has also shown potent antimycobacterial activity against MAC, with a low minimal inhibitory concentration in clinical isolates[@B73][@B74]. Only one case series has been published for NTM-PD, which included 10 patients (six with MAC and four with *M. abscessus*) with refractory NTM-PD and which showed a microbiologic response in 60% of patients and one or more negative cultures in 50% of patients[@B75]. Further large studies are needed to confirm the efficacy and safety of bedaquiline for the treatment of refractory or macrolide-resistant MAC-PD.

Definition of Treatment Outcomes
================================

In contrast to tuberculosis, NTM-PD has no widely accepted treatment outcome definitions and this lack of consensus may decrease the quality and interpretability of results from clinical trials and retrospective cohort studies. Recently, a consensus statement[@B76], proposed definitions for culture conversion, microbiological cure, clinical cure, treatment failure, recurrence, relapse, reinfection, death, and unknown outcomes ([Table 3](#T3){ref-type="table"}). These uniform definitions could improve the quality of evidence for NTM-PD treatment.

Although the current treatment outcome definitions were primarily based on the results of negative sputum culture conversion rate or cure and mortality, patient-centered approach outcome measurement was also important in patients management and clinical studies[@B77]. Patients with NTM-PD have significantly impaired health-related quality of life (HRQL) that is closed associated lung function[@B78][@B79][@B80][@B81][@B82][@B83]. Therefore, improvement of HRQL may be a reasonable treatment goal for patients with this chronic and difficult-to-treat NTM-PD[@B84]. More studies are needed for clarifying the standard assessment for HRQL in patients with NTM-PD which can guide appropriate therapeutic strategies in NTM-PD.

Conclusion
==========

The incidence and prevalence of NTM-PD have been rapidly increasing worldwide, with MAC the most common pathogen. Proper and timely treatment should be considered when patients have any of the prognostic factors for disease progression: a low body mass index, poor nutritional status, cavitary lesion(s), extensive disease, or positive AFB smear. When initiating treatment of MAC-PD, a guideline-recommended, macrolide-based combination therapy using three oral drugs should be started and maintained for at least 12 months after sputum culture conversion to negative. MAC-PD with treatment failure or macrolide resistance is usually refractory to medical treatment alone. Surgical treatment can increase the number of successful treatment outcomes in these patients with localized disease. However, as the complication rates of surgical treatment can be high, surgical resection should be considered following a rigorous risk-benefit analysis in a multidisciplinary setting and should be performed in an experienced center. New and repurposed drugs including clofazimine, inhaled amikacin, and bedaquiline have shown promising results, and further studies of their efficacy and safety are needed. Recently, consensus definitions on culture conversion, microbiological and clinical cure, treatment failure, recurrence, relapse, reinfection, death, and unknown outcomes of NTM-PD were developed and should be used to increase the quality of evidence for treating NTM-PD.
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![Treatment initiation algorithm for treatment naïve MAC-PD. Treatment should be considered when patients have risk factors for disease progression, including cavitary lesion(s), low body mass index, poor nutritional status, extensive disease, and AFB smear-positive sputum. If patients have mild disease and no risk factors for progression, treatment should be initiated when patients exhibit disease progression. MAC-PD: *Mycobacterium avium* complex pulmonary disease; HRCT: high-resolution computed tomography; AFB: acid-fast bacilli.](trd-82-15-g001){#F1}

![Fibrocavitary form of *Mycobacterium intracellulare* pulmonary disease in a 57-year-old male patient. (A) Chest high-resolution computed tomography (HRCT) shows a large, thick-walled cavity in the right upper lobe. (B) After 12 months of daily azithromycin, ethambutol, and rifampin treatment in combination with streptomycin injection for the initial 3 months, chest HRCT showed improvement of the cavitary lesion.](trd-82-15-g002){#F2}

![Cavitary nodular bronchiectatic form of *Mycobacterium avium* pulmonary disease in a 61-year-old female patient. (A) Chest high-resolution computed tomography (HRCT) shows severe bronchiectasis in the lingular segment of the left upper lobe. Note the cavity and multiple nodules suggesting bronchiolitis in the left lower lobe. (B) After 12 months of daily azithromycin, ethambutol, and rifampin treatment, chest HRCT showed improvement of cavitary and nodular lesions.](trd-82-15-g003){#F3}

![Non-cavitary nodular bronchiectatic form of pulmonary disease caused by *Mycobacterium intracellulare* in a 57-year-old female patient. (A) Chest high-resolution computed tomography (HRCT) shows severe bronchiectasis in the right middle lobe and the lingular segment of the left upper lobe. Note the peribronchiectatic consolidation, the multiple, small nodules, and tree-in-bud appearances suggesting bronchiolitis in both lungs. (B) After 12 months of three-times-weekly antibiotic therapy that included azithromycin, ethambutol, and rifampin, chest HRCT showed a decreased extent of bilateral consolidation and improvement of bronchiolitis.](trd-82-15-g004){#F4}

###### Summary of studies with meta-analysis on treatment outcomes of *Mycobacterium avium* complex pulmonary disease

![](trd-82-15-i001)

  Study                                                                                                  No. of studies    No. of patients   Selection criteria of studies                                                                                                                                                       Definition of treatment success                          Treatment success rate (% or 95% CI)                                        Other outcomes
  ------------------------------------------------------------------------------------------------------ ----------------- ----------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------------------
  Field et al. (2004)[@B35]                                                                              38                1,152             All                                                                                                                                                                                 Variable                                                 Prior to introduction of ethambutol or rifampin: 32                         
  Regimens included ethambutol and/or rifampin: 39                                                                                                                                                                                                                                                                                                                                                                                                                    
  Macrolide-containing regimens: 56                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Xu et al. (2014)[@B36]                                                                                 28                2,422             Studies with cases of culture-confirmed MAC by ATS guidelines, outcome definitions specified by mycobacterial culture, and outcomes reported according to the ATS classifications   Variable, specified by mycobacterial culture endpoints   39 (38--41)                                                                 Failure 27 (25.29)
  Treatment success rate of regimens with macrolide vs. without macrolide, 42 (40--44) vs. 28 (24--32)   Relapse 6 (5.7)                                                                                                                                                                                                                                                                                                                                              
  Death 17 (15.18)                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Default 12 (11.13)                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Kwak et al. (2017)[@B37]                                                                               16                1,462             Randomized, controlled trials and observational studies published in peer-reviewed journals                                                                                         12 Months of sustained culture negativity                60 (55--65)                                                                 Default rate of all studies vs. studies with tiw dosing: 16 (12--20) vs. 12 (9--15)
  Pasipanodya et al. (2017)[@B38]                                                                        21                2,534             Clinical trials, prospective and retrospective studies                                                                                                                              Sputum culture conversion                                6-Month culture conversion with macrolide-containing regimen: 65 (58--72)   
  Culture conversion at the end of treatment with macrolide-containing regimens: 64 (55--73)                                                                                                                                                                                                                                                                                                                                                                          
  Culture conversion at the end of treatment with macrolide-free regimens: 53 (15--89)                                                                                                                                                                                                                                                                                                                                                                                
  Sustained culture conversion with macrolide-containing regimens: 54 (45--63)                                                                                                                                                                                                                                                                                                                                                                                        
  Sustained culture conversion with macrolide-free regimens: 38 (25--52)                                                                                                                                                                                                                                                                                                                                                                                              
  Diel et al. (2018)[@B39]                                                                               42                2,376             Clinical trials, prospective and retrospective studies                                                                                                                              Sputum culture conversion                                Culture conversion with macrolidecontaining regimen: 52 (45--60)            
  Culture conversion with ATSrecommended three-drug regimen: 61 (50--73)                                                                                                                                                                                                                                                                                                                                                                                              
  Culture conversion with ATSrecommended three-drug regimen after more than 1 year: 66 (53--77)                                                                                                                                                                                                                                                                                                                                                                       

CI: confidence interval; MAC: *Mycobacterium avium* complex; ATS: American Thoracic Society; tiw: three times weekly.

###### Treatment of *Mycobacterium avium* complex pulmonary disease

![](trd-82-15-i002)

  Indications                                                  Regimen                                                                                                                                                                Duration of therapy
  ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------
  Non-cavitary nodular bronchiectatic form                     Azithromycin 500 mg tiw or clarithromycin 1,000 mg tiw and rifampin 600 mg tiw and ethambutol 25 mg/kg tiw                                                             12 Months beyond sputum culture conversion to negative
  Fibrocavitary form or cavitary nodular bronchiectatic form   Azithromycin 250--500 mg daily or clarithromycin 1000 mg daily and rifampin 450--600 mg daily and ethambutol 15 mg/kg daily and/or amikacin 15 mg/kg IV or IM tiw      12 Months beyond sputum culture conversion to negative
  Macrolide-resistant                                          Rifampin 450--600 mg daily and ethambutol 15 mg/kg daily and/or moxifloxacin 400 mg daily and/or clofazimine 100 mg daily and/or inhaled amikacin and/or bedaquiline   12 Months beyond sputum culture conversion to negative

tiw: three times weekly; IV: intravenous injection; IM: intramuscular injection.

###### International expert consensus on treatment outcome definitions for non-tuberculous mycobacterial pulmonary diseases

![](trd-82-15-i003)

  Outcome                Definition
  ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Culture conversion     The finding of at least three consecutive negative mycobacterial cultures from respiratory samples, collected at least 4 weeks apart, during antimycobacterial treatment
  Microbiological cure   Finding multiple consecutive negative but no positive cultures with the causative species from respiratory samples after culture conversion and until the end of antimycobacterial treatment
  Clinical cure          Patient-reported and/or objective improvement of symptoms during antimycobacterial treatment, sustained until at least the end of treatment, but no cultures available to prove culture conversion or microbiological cure
  Cure                   Antimycobacterial treatment completed, with fulfilment of criteria for both microbiological and clinical cure
  Treatment failure      The re-emergence of multiple positive cultures or persistence of positive cultures with the causative species from respiratory samples after ≥12 months of antimycobacterial treatment, while the patient is still on treatment
  Recurrence             The re-emergence of at least two positive cultures with the causative species from respiratory samples after cessation of antimycobacterial treatment
  Relapse                The emergence of at least two positive cultures with the same strain of the causative species after the end of treatment
  Reinfection            The emergence of at least two positive cultures with a different strain of the causative species or a strain of a different species after the initiation of the treatment episode
  Death                  Death due to any reason during treatment of NTM-PD
  Death due to NTM-PD    All causes of death that would not have occurred if the patient had not had NTM-PD
  Treatment halted       Physician- or patient-initiated pre-term cessation of antimycobacterial treatment
  Unknown outcome        Patient is no longer seen by his/her treating physician, so follow-up of treatment outcome is not possible (umbrella term for "lost to follow-up" and "transfer out")

Reprinted from van Ingen et al. Eur Respir J 2018;51:1800170, with permission of the European Respiratory Society[@B76].

NTM-PD: nontuberculous mycobacterial pulmonary disease.
